Nature Reviews Drug Discovery

Article	Citations
Engineering precision nanoparticles for drug delivery	3059
Natural products in drug discovery: advances and opportunities	1932
The COVID-19 vaccine development landscape	1179
Advances in oligonucleotide drug delivery	1000
Targeting oxidative stress in disease: promise and limitations of antioxidant therapy	935
PROTAC targeted protein degraders: the past is prologue	880
Trends in peptide drug discovery	773
Noncoding RNA therapeutics — challenges and potential solutions	721
Emerging concepts in the science of vaccine adjuvants	581
mRNA vaccines for infectious diseases: principles, delivery and clinical translation	559
RAS-targeted therapies: is the undruggable drugged?	540
Kinase drug discovery 20 years after imatinib: progress and future directions	483
Targeting inflammation in atherosclerosis — from experimental insights to the clinic	438
Organs-on-chips: into the next decade	435
Evolution of the COVID-19 vaccine development landscape	433
Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing	424
Macrophages as tools and targets in cancer therapy	416
Strategies for delivering therapeutics across the blood–brain barrier	400
Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine	374
Targeting cancer metabolism in the era of precision oncology	373
Radiopharmaceutical therapy in cancer: clinical advances and challenges	357
Anti-obesity drug discovery: advances and challenges	340
Trends in kinase drug discovery: targets, indications and inhibitor design	324
Channelling inflammation: gasdermins in physiology and disease	306
FDA approves 100th monoclonal antibody product	289

Antisense technology: an overview and prospectus	289
B cell depletion therapies in autoimmune disease: advances and mechanistic insights	285
The clinical landscape for AAV gene therapies	270
Poly(ADP-ribose) polymerase inhibition: past, present and future	267
The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics	261
The quest to slow ageing through drug discovery	253
Targeting the epigenetic regulation of antitumour immunity	251
Therapeutically harnessing extracellular vesicles	248
Targeted protein degraders crowd into the clinic	237
Navigating CAR-T cells through the solid-tumour microenvironment	231
Atopic dermatitis: an expanding therapeutic pipeline for a complex disease	229
Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target	218
PI3K inhibitors are finally coming of age	215
Kinase inhibition in autoimmunity and inflammation	211
Base editing: advances and therapeutic opportunities	210
The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans	205
Beyond immune checkpoint blockade: emerging immunological strategies	201
Advances in TRP channel drug discovery: from target validation to clinical studies	195
The foundations of immune checkpoint blockade and the ipilimumab approval decennial	189
Zebrafish disease models in drug discovery: from preclinical modelling to clinical trials	189
Image-based profiling for drug discovery: due for a machine-learning upgrade?	188
Therapeutic strategies for thrombosis: new targets and approaches	182
Protein arginine methylation: from enigmatic functions to therapeutic targeting	181
Emerging therapeutic opportunities for integrin inhibitors	181
Advances in covalent drug discovery	175
Circadian rhythm as a therapeutic target	169
Identification of neoantigens for individualized therapeutic cancer vaccines	166
Therapeutic strategies targeting FOXO transcription factors	160
Advances in therapeutic peptides targeting G protein-coupled receptors	159
RNA therapeutics on the rise	159
Pharmacological targeting of endoplasmic reticulum stress in disease	156
Function and therapeutic value of astrocytes in neurological diseases	154
Next-generation stem cells — ushering in a new era of cell-based therapies	153
Advances in targeting ‘undruggable’ transcription factors with small molecules	146
Antitumour dendritic cell vaccination in a priming and boosting approach	142
Targeting Notch in oncology: the path forward	142
Drugging p53 in cancer: one protein, many targets	141
Targeting RNA structures with small molecules	138
2020 FDA drug approvals	138
Engineering living therapeutics with synthetic biology	136
Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities	132
Targeting HER2-positive breast cancer: advances and future directions	129
Lipogenesis inhibitors: therapeutic opportunities and challenges	121
Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease	112
The PROTACtable genome	112
Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies	111
Therapeutic strategies for COVID-19: progress and lessons learned	107
The emerging role of mass spectrometry-based proteomics in drug discovery	107
Targeting co-stimulatory molecules in autoimmune disease	104
Impact of COVID-19 on oncology clinical trials	96

Exosome-based candidates move into the clinic	94
Combinations take centre stage in PD1/PDL1 inhibitor clinical trials	92
A tale of two antiviral targets — and the COVID-19 drugs that bind them	89
Drugging the efferocytosis process: concepts and opportunities	87
Modulating biomolecular condensates: a novel approach to drug discovery	87
Engineering the next generation of cell-based therapeutics	86
Immune targets for therapeutic development in depression: towards precision medicine	86
Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape	86
Human genetics evidence supports two-thirds of the 2021 FDA-approved drugs	83
Improving target assessment in biomedical research: the GOT-IT recommendations	82
The glomerular filtration barrier: a structural target for novel kidney therapies	81
Targeting replication stress in cancer therapy	80
The promises and perils of psychedelic pharmacology for psychiatry	80
Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation	75
Phenotypic drug discovery: recent successes, lessons learned and new directions	74
Cancer cell therapies: the clinical trial landscape	73
2021 FDA approvals	72
Top companies and drugs by sales in 2019	69
Leveraging preclinical models for the development of Alzheimer disease therapeutics	69
Antibody–drug conjugates come of age in oncology	69
Trends in COVID-19 therapeutic clinical trials	68
Antibodies to combat viral infections: development strategies and progress	67
Double setback for ASO trials in Huntington disease	65
Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders	65
Rational combinations of targeted cancer therapies: background, advances and challenges	64
Avidity in antibody effector functions and biotherapeutic drug design	62
Immuno-oncology drug development forges on despite COVID-19	61
Soluble ligands as drug targets	61
Failure of first anti-tau antibody in Alzheimer disease highlights risks of history repeating	61
Ligand binding at the protein–lipid interface: strategic considerations for drug design	58
The oncology market for antibody–drug conjugates	58
Engineering islets from stem cells for advanced therapies of diabetes	58
What does AlphaFold mean for drug discovery?	56
Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment	56
Gene therapy community grapples with toxicity issues, as pipeline matures	56
Breaking Eroom’s Law	55
Exercise mimetics: harnessing the therapeutic effects of physical activity	54
Clinical development times for innovative drugs	53
Phase 0/microdosing approaches: time for mainstream application in drug development?	53
The RESOLUTE consortium: unlocking SLC transporters for drug discovery	52
Restoring IL-2 to its cancer immunotherapy glory	50
The expanding role for small molecules in immuno-oncology	50
Deuterium in drug discovery: progress, opportunities and challenges	49
AI in small-molecule drug discovery: a coming wave?	49
Clinical trial recovery from COVID-19 disruption	47
Pan-coronavirus vaccine pipeline takes form	47
The glymphatic system: implications for drugs for central nervous system diseases	46
Targeting galectin-driven regulatory circuits in cancer and fibrosis	45
Addressing cancer’s grand challenges	44
Landscape of cancer cell therapies: trends and real-world data	42
Targeting receptor complexes: a new dimension in drug discovery	42
Bispecific antibodies in oncology	42
Strategies to access biosynthetic novelty in bacterial genomes for drug discovery	41
Modulating gene regulation to treat genetic disorders	41
Harnessing the predictive power of preclinical models for oncology drug development	40
Emerging principles of cytokine pharmacology and therapeutics	40
Top companies and drugs by sales in 2021	39
Top companies and drugs by sales in 2020	39
Targeting angiogenesis in oncology, ophthalmology and beyond	37
2022 FDA approvals	36
Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems	35
Base editors hit the clinic	34
Digital technologies for medicines: shaping a framework for success	34
Antibody–oligonucleotide conjugates enter the clinic	33
mRNA flu shots move into trials	33
Adoption of organ-on-chip platforms by the pharmaceutical industry	32
Gene-editing pipeline takes off	32
Thinking outside the box: non-canonical targets in multiple sclerosis	31
FDA approves fourth CAR-T cell therapy	30
Trends in the approval of cancer therapies by the FDA in the twenty-first century	30
Applications of single-cell RNA sequencing in drug discovery and development	29
VEGFA mRNA for regenerative treatment of heart failure	29
Monitoring protein communities and their responses to therapeutics	28
The evolving role of investigative toxicology in the pharmaceutical industry	28
FDA approves first BCMA-targeted CAR-T cell therapy	28
mRNA vaccines: intellectual property landscape	28
Beyond PI3Ks: targeting phosphoinositide kinases in disease	26
The therapeutic potential of targeting regulated non-apoptotic cell death	26
p53 programmes plough on	25
First microbiome-based drug clears phase III, in clinical trial turnaround	25

Accelerating antiviral drug discovery: lessons from COVID-19	25
Remote digital monitoring in clinical trials in the time of COVID-19	24
Trends in oncology drug innovation in China	23
Therapeutic RNA-silencing oligonucleotides in metabolic diseases	23
Characteristics of expedited programmes for cancer drug approval in China	23
Informing single-arm clinical trials with external controls	22
FDA approval for Biogen’s aducanumab sparks Alzheimer disease firestorm	22
The clinical pipeline for cancer cell therapies	22
Predictive validity in drug discovery: what it is, why it matters and how to improve it	22
Author Correction: Targeting oxidative stress in disease: promise and limitations of antioxidant therapy	21
First de novo deuterated drug poised for approval	21
Amplifying gene expression with RNA-targeted therapeutics	20
Stemming the tide of drug resistance in cancer	19
The mRNA vaccine development landscape for infectious diseases	19
The breast cancer drug market	19
COVID-19 impact on oncology clinical trials: a 1-year analysis	19
Derivatization with fatty acids in peptide and protein drug discovery	19
Targeting protein phosphatases in cancer immunotherapy and autoimmune disorders	19
Using human genetics to improve safety assessment of therapeutics	18
Evolution of the market for mRNA technology	18
HCAR3: an underexplored metabolite sensor	17
Small-molecule discovery through DNA-encoded libraries	17
The landscape for lipid-nanoparticle-based genomic medicines	17
eEF2K: an atypical kinase target for cancer	16
ALS antisense drug falters in phase III	16
Implications of sex-related differences in central nervous system disorders for drug research and development	15
The KRAS crowd targets its next cancer mutations	15
Delivering on the promise of protein degraders	15
PIKfyve: a lipid kinase target for COVID-19, cancer and neurodegenerative disorders	14
Digital health technologies in clinical trials for central nervous system drugs: an EU regulatory perspective	14
Author Correction: RAS-targeted therapies: is the undruggable drugged?	14
FDA rejects NASH drug	14
Trends in innovative drug development in China	14
FDA approves second BCMA-targeted CAR-T cell therapy	14
BCKDK: an emerging kinase target for metabolic diseases and cancer	14
Pyroptosis heats tumour immunity	14
RAS-targeted therapies	14
The market for ulcerative colitis	13
Top companies and drugs by sales in 2022	13
Integrin-targeted therapies branch out	13
Boosting delivery of rare disease therapies: the IRDiRC Orphan Drug Development Guidebook	12
Industrializing engineered autologous T cells as medicines for solid tumours	12
COVID-19 must catalyse changes to clinical development	12
Improving data sharing to increase the efficiency of antibiotic R&D	12
Novel drug targets in 2019	12
Strategies to therapeutically modulate cytokine action	12
RECOVERY 1 year on: a rare success in the COVID-19 clinical trial landscape	12
FDA approves first gene therapy for Duchenne muscular dystrophy, despite internal objections	12
AAV-based in vivo gene therapy for neurological disorders	11
Artificial intelligence for natural product drug discovery	11
Long COVID’s long R&D agenda	11
PIP5K1A: a potential target for cancers with KRAS or TP53 mutations	11
Type 2 chronic inflammatory diseases: targets, therapies and unmet needs	11
Application of Bayesian approaches in drug development: starting a virtuous cycle	11
The prostate cancer drug market	11
NfL makes regulatory debut as neurodegenerative disease biomarker	11
Small activating RNAs lead the charge to turn up gene expression	10
First CRISPR therapy seeks landmark approval	10
FDA approves first haemophilia B gene therapy	10
Immune status could determine efficacy of COVID-19 therapies	10
Antimalarial drug discovery: progress and approaches	10
LAG3 pushes immuno-oncology’s leading edge	10
Author Correction: Trends in kinase drug discovery: targets, indications and inhibitor design	10
opnMe.com: a digital initiative for sharing tools with the biomedical research community	10
Trispecific antibodies take to the clinic	10
RSV vaccines score landmark FDA approvals	10
A future for regulatory science in the European Union: the European Medicines Agency’s strategy	10
Error-corrected next-generation sequencing to advance nonclinical genotoxicity and carcinogenicity testing	10
Targeting synapse function and loss for treatment of neurodegenerative diseases	9
The failure to fail smartly	9
Orphan drug designation and development in Japan: 25 years of experience and assessment	9
Top product forecasts for 2022	9
Can anti-inflammatory strategies light up the dim depression pipeline?	9
Evolution of innovative drug R&D in China	9
Comparing development strategies for PD1/PDL1-based immunotherapies	9
Transferrin’ across the blood–brain barrier	8
Drug delivery systems for CRISPR-based genome editors	8
Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies	8
Author Correction: Next-generation influenza vaccines: opportunities and challenges	8
FDA approves fifth RNAi drug — Alnylam’s next-gen hATTR treatment	8
FDA approves AstraZeneca’s anifrolumab for lupus	8
Targeted protein degraders: a call for collective action to advance safety assessment	8
Fragment-based screening sees the light	8
Accelerating therapeutic discoveries for heart failure: a new public–private partnership	8
LRRK2-targeted Parkinson disease drug advances into phase III	8
Amgen overcomes historically undruggable target, with FDA nod for first KRAS inhibitor	8
Therapeutic approaches for Duchenne muscular dystrophy	7
Novel drug targets in 2021	7
‘Bespoke Gene Therapy Consortium’ sets out to enable gene therapies for ultra-rare diseases	7
The most successful oncology drug portfolios of the past decade	7
Author Correction: mRNA vaccines for infectious diseases: principles, delivery and clinical translation	7
Translational misconceptions	7
CDC42BPA/MRCKα: a kinase target for brain, ovarian and skin cancers	7
What’s next for the synthetic lethality drug discovery engine?	7
Research on rare diseases: ten years of progress and challenges at IRDiRC	7